Table of contents

Immune cell therapies and immune cell engineering

• Original research: An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells (31 May, 2024)

  Matthew Ryan Sullivan, Michael Finocchiaro, Yichao Yang, Judene Thomas, Alaa Ali, Isabel Kaplan, Yasmin Abdulhamid, Eden Bobilev, Michal Sheffer, Rizwan Romee, Tania Konry
• Original research: Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes (30 May, 2024)

  Noam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu, Sivasish Sindiri, Jared J Gartner, Maria Parkhurst, Sri Krishna, Frank J Lowery, Nikolaos Zacharakis, Lior Levy, Todd D Prickett, Tiffany Benzine, Satyajit Ray, Robert V Masi, Billel Gasmi, Yong Li, Rafiqul Islam, Alakesh Bera, Stephanie L Goff, Paul F Robbins, Steven A Rosenberg
• Original research: Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China (27 May, 2024)

  Wenyan Yu, Liang Huang, Heng Mei, Yuhua Li, Ting Niu, Dehui Zou, Yao Liu, Huilai Zhang, Peng Liu, Jianqiu Wu, Zhi Wang, Hui Li, Qingqing Cai, Jian-qing Mi
• Original research: Developing a membrane-proximal CD33-targeting CAR T cell (20 May, 2024)

  Ruby Freeman, Sanam Shahid, Abdul G Khan, Serena C Mathew, Sydney Souness, Erin R Burns, Jasmine S Um, Kento Tanaka, Winson Cai, Sarah Yoo, Andrew Dunbar, Young Park, Devin McAvoy, Kinga K Hosszu, Ross L Levine, Jaap Jan Boelens, Ivo C Lorenz, Renier J Brentjens, Anthony F Daniyan
• Original research: Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings (15 May, 2024)

  Nicolas Poirier, Valérie Paquin, Séverine Leclerc, Véronique Lisi, Carolina Marmolejo, Hicham Affia, Paulo Cordeiro, Yves Théorêt, Elie Haddad, Gregor Andelfinger, Vincent Philippe Lavallée, Michel Duval, Sabine Herblot
• Original research: Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers (15 May, 2024)

  Tessa Gargett, Nga T H Truong, Bryan Gardam, Wenbo Yu, Lisa M Ebert, Amy Johnson, Erica C F Yeo, Nicole L Wittwer, Gonzalo Tapia Rico, Jesikah Logan, Purany Sivaloganathan, Maria Collis, Andrew Ruszkiewicz, Michael P Brown
• Original research: Stealth transgenes enable CAR-T cells to evade host immune responses (9 May, 2024)

  Korneel Grauwet, Trisha Berger, Michael C Kann, Harrison Silva, Rebecca Larson, Mark B Leick, Stefanie R Bailey, Amanda A Bouffard, David Millar, Kathleen Gallagher, Cameron J Turtle, Matthew J Frigault, Marcela V Maus